Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations
Breast Cancer

Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations

In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms

Read more

Don't miss

  • Keynote lecture: Optimising adjuvant treatment in HR+/HER2 negative early breast cancer
    3 May 2022, 15:40-16:10, Berlin Hall
  • Special session on the Ukraine: How many wars to fight?
    4 May 2022, 11:35-12:20, Cologne Hall
  • Keynote lecture: How shall our knowledge of cancer evolution transform breast oncology?
    4 May 2022, 14:10-14:40, Berlin Hall

EDITORIAL

HIGHLIGHTS

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.